2nd Proteomic Based Drug Discovery Summit 2026

With Novartis committing $750M to ProFound Therapeutics to discover new cardiovascular candidates, and Illumina acquiring SomaLogic for $425 to expand its proteomic capabilities just this year alone, the increasing recognition of proteomics as a transformative force in drug discovery is unquestionable.

Returning to Boston for its second year, the Proteomics-Based Drug Discovery Summit is the premier industry event dedicated to harnessing the full power of proteomics across drug discovery pipelines. Designed for scientific innovators like you, explore how next-generation proteomic platforms are accelerating understanding of pathology, unveiling novel drug targets, and transforming hit-to-lead development.

With a special focus on optimizing proteomics instruments to balance throughput and sensitivity, automating sample processing, unveiling hidden disease mechanisms with PTM analysis, and defining gold-standard analysis methodologies; this forum is ideal for proteomics leaders aiming to expand the druggable proteome and achieve therapeutic options for diseases with unmet need.

As proteomics continues to evolve, make headlines, and revolutionize therapeutic development, unite with 70+ Directors, Vice President and Experts in Proteomics, Chemical Biology, Mass Spectrometry and Bioinformatics to achieve protein level insights to advance your own discovery pipeline.

URLs:
Website: https://go.evvnt.com/3297893-0?pid=2874
Brochure: https://go.evvnt.com/3297893-3?pid=2874

Category: Conferences | Science, Health and Medicine | Pharmaceuticals | Drug Discovery

Prices:
Drug Developer Pricing - 3 Day Pass (2 Workshops + Conference): USD 4197.00,
Drug Developer Pricing - 3 Day Pass (1 Workshop + Conference): USD 3598.00,
Drug Developer Pricing - 2 Day Pass (Conference Only): USD 2999.00,
Academic Pricing - 3 Day Pass (2 Workshops + Conference): USD 3597.00,
Academic Pricing - 3 Day Pass (1 Workshop + Conference): USD 3098.00,
Academic Pricing - 2 Day Pass (Conference Only): USD 2599.00,
Service Provider Pricing - 3 Day Pass (2 Workshops + Conference): USD 5197.00,
Service Provider Pricing - 3 Day Pass (1 Workshop + Conference): USD 4498.00,
Service Provider Pricing - 2 Day Pass (Conference Only): USD 3799.00

Speakers: Satya Saxena, Director of Global Proteomics, Eisai, Harris Bell-Temin, Director, Proteomics, Johnson and Johnson, An Chi, Senior Director, Merck and Co, Ansgar Brock, Associate Director, Novartis, Liang Xue, Director, Bioinformatics, Pfizer, Monica Lane, Associate Director, Genomic Medicine and Bioanalytics Characterization, Sanofi, Joon Jung, Senior Vice President, Head of Data Science, Acrivon Therapeutics, Lauren Stopfer, Executive Director of Proteomics and Innovation, Aethon Therapeutics, John Corradi, Director, Proteomics and Bioinformatics, Arvinas, Ben Ruprecht, Director, Proteomics, Blueprint Medicines, Mauricio Cortes, Senior Director, Head of Discovery Science, Cellarity, Emanuela Milani-Tschudy, Vice President, Technology, DISCO Pharmaceuticals, Antony Burton, Associate Director, Chemical Biology and Proteomics, Dunad Therapeutics, Karsten Krug, Director, Head of Bioinformatics, Frontier Medicines, Christoph Schräder, Associate Director, Immatics, Landon Whitby, Director, Chemical Biology and Proteomics, Light Horse Therapeutics, Stella Ritorto, Senior Director and Head of Mass Proteomics, ProFound Therapeutics, Joel Chick, Vice President, Proteomics Discovery, RyboDyn, Morgan Stykel, Senior Scientist, Aquinnah Pharmaceuticals, Uthpala Seneviratne, Associate Principal Scientist, AstraZeneca, Robert Salzler, Bioanalytical, Biomarker Technologies and Immunopeptidomics Professional, Regeneron, Michael Roehrl, Chair, Department of Pathology, Beth Israel Deaconess Medical Center, Katherine Donovan, Managing Director, Fischer Labs, Dana-Farber Cancer Institute, Nikolai Slavov, Professor, Northeastern University